Additional Information

Description

A twelve-panel urine drug screening system engineered for rapid detection delivers simultaneous qualitative evaluation of multiple drug metabolites through an integrated lateral-flow immunoassay structure. The unit incorporates a sealed click-activation mechanism that initiates fluid migration immediately upon specimen introduction, removing the need for manual reagent handling. Sterile manufacturing controls sustain integrity for clinical and occupational screening environments requiring consistent performance.

The analytical membrane array is configured to detect amphetamines, barbiturates, buprenorphine, benzodiazepines, cocaine metabolites at 150 ng/mL, MDMA, methamphetamine at 500 ng/mL, opiates at 300 ng/mL, methadone, oxycodone, phencyclidine, and tetrahydrocannabinol. Integrated adulterant checks for oxidants, specific gravity, and pH provide assessment of specimen validity, enhancing reliability by identifying abnormal chemical conditions suggestive of tampering or dilution.

Construction features include a tamper-evident cup body with clear result windows allowing direct visual assessment of test and control line development. The internal reagent design ensures stable migration and defined endpoint formation within a controlled time frame appropriate for CLIA-waived environments. This structure supports rapid procedural workflows while maintaining standardized interpretive accuracy.